Navigation Links
Plavix may be treatment for dogs at risk of thromboembolic disease
Date:7/14/2010

Athens, Ga. Companion animals that have a long-term need for anticoagulant drug therapies may soon find help in a top-selling antiplatelet drug marketed to humans: clopidogrel, commonly known by the trade-name Plavix.

Researchers in the University of Georgia College of Veterinary Medicine have found that clopidogrel may be a safe and effective treatment for dogs that need long-term anticoagulant therapy. In addition, it may offer a safe alternative to NSAIDs for treating dogs at risk of thromboembolism due to concurrent therapeutic use of corticosteroids.

Other than aspirin, there are currently no approved antiplatelet drug therapies available to prophylactically treat companion animals with known or suspected hypercoagulability. Anticoagulants such as heparin, which must be administered by injection, are often used instead, but for patients who need long-term treatment, the researchers on the study said many animal owners are reluctant to administer injectable drugs to their pets.

In addition, critically ill dogs are at risk for thromboembolic disease, including pulmonary and aortic thromboembolism, both of which are associated with severe illness and death. Dogs that develop thrombosis and are subsequently treated with thrombolytic agents are at a substantial risk of hemorrhage or metabolic instability.

The researchers wanted to evaluate clopidogrel as a potential treatment for dogs with hypercoagulability due to excessive platelet activation. Clopidogrel, which is only available as an oral therapy, has been safely administered to cats, rabbits and calves, but little has been published about its effects in dogs.

In a study of healthy dogs, researchers found that most dogs had a significant inhibition of platelet function within three hours of receiving clopidogrel. All of the dogs in the study tolerated the drug well and showed no evidence of bruising, hemorrhage or other adverse effects. In addition, platelet activity returned to normal levels within approximately seven days after the drug was discontinued, which is similar to the response found in humans.

The researchers caution that their study only provides data on the effectiveness of clopidogrel in healthy dogs, and not on dogs that are critically ill or receiving other drugs. Further pharmacokinetic and pharmacodynamic studies in critically ill canine patients are planned, in addition to studies evaluating this drug in healthy horses.


'/>"/>

Contact: Kat Gilmore
kygilmore@uga.edu
706-583-5485
University of Georgia
Source:Eurekalert

Related biology news :

1. Breast cancer treatment resistance linked to signaling pathway
2. The dietary supplement genistein can undermine breast cancer treatment
3. Coming soon: Self-guided, computer-based depression treatment
4. Nanodiamond drug device could transform cancer treatment
5. Disinfectants can make bacteria resistant to treatment
6. Scientists from Granada find a potential treatment to prevent diabetes and obesity
7. FSU researchers discovery leads to $1.5 million grant, potential new treatment of liver fibrosis
8. Researchers at National Jewish Health evaluating a treatment
9. National Jewish Health researchers evaluating treatment to help emphysema sufferers breathe easier
10. First comprehensive genomic study of common cold reveals new treatment targets
11. Iowa State researcher develops new treatment method for canine eye diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Texas , Dec. 1, 2016   ... today announced BioLock , an electrocardiogram (ECG) ... health monitoring, a key IoT asset. The smart ... into a vehicle,s steering wheel and mobile devices ... simple touch. As vehicle technology advances, ...
(Date:11/29/2016)... November 29, 2016 Nearly one billion matches per ... ... DERMALOG is ... an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint ...
(Date:11/21/2016)... 21, 2016   Neurotechnology , a provider ... today announced that the MegaMatcher On Card fingerprint ... for the NIST Minutiae Interoperability Exchange (MINEX) ... mandatory steps of the evaluation protocol. ... test of fingerprint templates used to establish compliance ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... Lajollacooks4u, San Diego’s premier team ... for team building events, new program offerings and company expansion. , This ... year to include groups of over 30 people. Ever since, Lajollacooks4u has seen significant ...
(Date:12/8/2016)... India , December 8, 2016 ... a comprehensive analysis, titled Global Amyloglucosidase Industry 2016 Market Research ... classification, application, and industry chain overview are all covered in ... SWOT analysis, and investment return analysis of the Amyloglucosidase industry. ... , , ...
(Date:12/8/2016)... , Dec. 8, 2016 Eurofins announces the appointment of ... President of Eurofins Scientific Inc. (ESI). Mr. Murray ... proven professional and entrepreneurial experience in leading international business teams. As ... food testing market to uphold Eurofins, status as the global leader ... , ...
(Date:12/8/2016)... England , December 8, 2016 ... das Unternehmen für Molekulargenetik, erweitert seine Palette an ... myPanel™ NGS Custom FH Panels, das ein schnelles ... (FH) ermöglicht. Das Panel bietet eine Erkennung von ... Variations (CNV) mit einem einzigen kleinen Panel und ...
Breaking Biology Technology: